☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Regeneron
Regeneron Showcases Updated P-I/II (LINKER-MM1) Study Data of Linvoseltamab for Treating R/R Multiple Myeloma at EHA 2024
June 17, 2024
Regeneron’s Kevzara (Sarilumab) Gains the US FDA’s Approval to Treat Active Polyarticular Juvenile Idiopathic Arthritis (PJIA)
June 11, 2024
Regeneron and Sanofi Report the US FDA’s sBLA Acceptance of Dupixent to Treat Chronic Rhinosinusitis with Nasal Polyposis (CRSWNP)
May 13, 2024
Regeneron Reports Results from the P-I/II (CHORD) Study of DB-OTO for Hearing Loss
May 9, 2024
Regeneron Reports the Acceptance of its MAA by the EMA for Linvoseltamab to Treat Multiple Myeloma (MM)
February 5, 2024
Regeneron Reports Positive Results of Odronextamab in P-II (ELM-2) Trial for the Treatment of Follicular Lymphoma
December 12, 2023
Load more...
Back to Home